Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

Cited In for PubMed (Select 19595768)

1.

Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First?

Zaltieri M, Longhena F, Pizzi M, Missale C, Spano P, Bellucci A.

Parkinsons Dis. 2015;2015:108029. doi: 10.1155/2015/108029. Epub 2015 Mar 31. Review.

2.

Excessive levels of nitric oxide in rat model of Parkinson's disease induced by rotenone.

Xiong ZK, Lang J, Xu G, Li HY, Zhang Y, Wang L, Su Y, Sun AJ.

Exp Ther Med. 2015 Feb;9(2):553-558. Epub 2014 Dec 2.

3.

Olfactory impairment in the rotenone model of Parkinson's disease is associated with bulbar dopaminergic D2 activity after REM sleep deprivation.

Rodrigues LS, Targa AD, Noseda AC, Aurich MF, Da Cunha C, Lima MM.

Front Cell Neurosci. 2014 Dec 1;8:383. doi: 10.3389/fncel.2014.00383. eCollection 2014.

4.

Models of α-synuclein aggregation in Parkinson's disease.

Giráldez-Pérez R, Antolín-Vallespín M, Muñoz M, Sánchez-Capelo A.

Acta Neuropathol Commun. 2014 Dec 13;2:176. doi: 10.1186/s40478-014-0176-9. Review.

5.

Mitochondrial DNA damage as a peripheral biomarker for mitochondrial toxin exposure in rats.

Sanders LH, Howlett EH, McCoy J, Greenamyre JT.

Toxicol Sci. 2014 Dec;142(2):395-402. doi: 10.1093/toxsci/kfu185. Epub 2014 Sep 18.

PMID:
25237061
6.

Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.

Kelly LP, Carvey PM, Keshavarzian A, Shannon KM, Shaikh M, Bakay RA, Kordower JH.

Mov Disord. 2014 Jul;29(8):999-1009. doi: 10.1002/mds.25736. Epub 2013 Nov 4.

7.

Unexpected improvements of spatial learning and memory abilities in chronic rotenone intoxicated mice.

Jia F, Song N, Zhao C, Xie J, Jiang H.

PLoS One. 2014 Mar 11;9(3):e91641. doi: 10.1371/journal.pone.0091641. eCollection 2014.

8.

Non-motor parkinsonian pathology in aging A53T α-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function.

Farrell KF, Krishnamachari S, Villanueva E, Lou H, Alerte TN, Peet E, Drolet RE, Perez RG.

J Neurochem. 2014 Feb;128(4):536-46. doi: 10.1111/jnc.12481. Epub 2013 Nov 20.

9.

Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications.

Chen H, Burton EA, Ross GW, Huang X, Savica R, Abbott RD, Ascherio A, Caviness JN, Gao X, Gray KA, Hong JS, Kamel F, Jennings D, Kirshner A, Lawler C, Liu R, Miller GW, Nussbaum R, Peddada SD, Rick AC, Ritz B, Siderowf AD, Tanner CM, Tröster AI, Zhang J.

Environ Health Perspect. 2013 Nov-Dec;121(11-12):1245-52. doi: 10.1289/ehp.1306967. Epub 2013 Aug 9. Review.

10.

Resveratrol confers protection against rotenone-induced neurotoxicity by modulating myeloperoxidase levels in glial cells.

Chang CY, Choi DK, Lee DK, Hong YJ, Park EJ.

PLoS One. 2013 Apr 8;8(4):e60654. doi: 10.1371/journal.pone.0060654. Print 2013.

11.

Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.

Sanders LH, Greenamyre JT.

Free Radic Biol Med. 2013 Sep;62:111-20. doi: 10.1016/j.freeradbiomed.2013.01.003. Epub 2013 Jan 15. Review.

12.

Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism.

Hauser DN, Hastings TG.

Neurobiol Dis. 2013 Mar;51:35-42. doi: 10.1016/j.nbd.2012.10.011. Epub 2012 Oct 12. Review.

13.

Living on the edge with too many mouths to feed: why dopamine neurons die.

Bolam JP, Pissadaki EK.

Mov Disord. 2012 Oct;27(12):1478-83. doi: 10.1002/mds.25135. Epub 2012 Sep 24.

14.

α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits.

Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O.

Neurobiol Dis. 2012 Aug;47(2):258-67. doi: 10.1016/j.nbd.2012.04.009. Epub 2012 Apr 19.

15.

Animal models of the non-motor features of Parkinson's disease.

McDowell K, Chesselet MF.

Neurobiol Dis. 2012 Jun;46(3):597-606. doi: 10.1016/j.nbd.2011.12.040. Epub 2012 Jan 3. Review.

16.

A guide to neurotoxic animal models of Parkinson's disease.

Tieu K.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a009316. doi: 10.1101/cshperspect.a009316. Review.

17.

Differential regional and subtype-specific vulnerability of enteric neurons to mitochondrial dysfunction.

Viader A, Wright-Jin EC, Vohra BP, Heuckeroth RO, Milbrandt J.

PLoS One. 2011;6(11):e27727. doi: 10.1371/journal.pone.0027727. Epub 2011 Nov 16.

18.

Bladder, bowel, and sexual dysfunction in Parkinson's disease.

Sakakibara R, Kishi M, Ogawa E, Tateno F, Uchiyama T, Yamamoto T, Yamanishi T.

Parkinsons Dis. 2011;2011:924605. doi: 10.4061/2011/924605. Epub 2011 Sep 12.

19.

Toxin models of mitochondrial dysfunction in Parkinson's disease.

Martinez TN, Greenamyre JT.

Antioxid Redox Signal. 2012 May 1;16(9):920-34. doi: 10.1089/ars.2011.4033. Epub 2011 Jul 12. Review.

20.

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Duty S, Jenner P.

Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk